QUIDELORTHO CORP Operating Income
QUIDELORTHO CORP (QDEL) reported Operating Income of -$21.80 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-07
- QUIDELORTHO CORP operating income (loss) for the quarter ending 2026-06-28 was -$21.80M.
- QUIDELORTHO CORP operating income (loss) for the quarter ending 2026-03-29 was -$31.80M, a 197.55% decline year-over-year.
- QUIDELORTHO CORP operating income (loss) for the quarter ending 2025-12-28 was -$66.30M.
- QUIDELORTHO CORP operating income (loss) for the quarter ending 2025-09-28 was -$704.80M, a 4798.67% decline year-over-year.
- QUIDELORTHO CORP operating income (loss) for fiscal 2025 was -$919.20M.
- QUIDELORTHO CORP operating income (loss) for fiscal 2024 was -$1.96B, a 1509.71% decline from fiscal 2023.
- QUIDELORTHO CORP operating income (loss) for fiscal 2023 was $139.10M, a 83.51% decline from fiscal 2023.
- QUIDELORTHO CORP operating income (loss) for fiscal 2023 was $843.70M, a 6.88% decline from fiscal 2022.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-28 | -$21.80M 10-Q · filed 2026-08-07 | -$53.60M 10-Q · filed 2026-08-07 | -$119.90M derived: sum of 3 quarters · filed 2026-08-07 | -$824.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-29 | -$31.80M 10-Q · filed 2026-05-06 | -$98.10M derived: sum of 2 quarters · filed 2026-05-06 | -$802.90M derived: sum of 3 quarters · filed 2026-05-06 | -$983.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-28 | -$66.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$771.10M derived: sum of 2 quarters · filed 2026-02-19 | -$951.80M derived: sum of 3 quarters · filed 2026-08-07 | -$919.20M 10-K · filed 2026-02-19 |
| 2025-09-28 | -$704.80M 10-Q · filed 2025-11-06 | -$885.50M derived: sum of 2 quarters · filed 2026-08-07 | -$852.90M 10-Q · filed 2025-11-06 | -$953.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-29 | -$180.70M 10-Q · filed 2026-08-07 | -$148.10M 10-Q · filed 2026-08-07 | -$248.50M derived: sum of 3 quarters · filed 2026-08-07 | -$233.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-30 | $32.60M 10-Q · filed 2026-05-06 | -$67.80M derived: sum of 2 quarters · filed 2026-05-06 | -$52.80M derived: sum of 3 quarters · filed 2026-05-06 | -$170.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-29 | -$100.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$85.40M derived: sum of 2 quarters · filed 2026-02-19 | -$202.90M derived: sum of 3 quarters · filed 2026-02-19 | -$1.96B 10-K · filed 2026-02-19 |
| 2024-09-29 | $15.00M 10-Q · filed 2025-11-06 | -$102.50M derived: sum of 2 quarters · filed 2025-11-06 | -$1.86B 10-Q · filed 2025-11-06 | -$1.82B derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$117.50M 10-Q · filed 2025-08-06 | -$1.88B 10-Q · filed 2025-08-06 | -$1.84B derived: sum of 3 quarters · filed 2026-02-19 | -$1.81B derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$1.76B 10-Q · filed 2025-05-08 | -$1.72B derived: sum of 2 quarters · filed 2026-02-19 | -$1.69B derived: sum of 3 quarters · filed 2026-02-19 | -$1.72B derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $40.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $66.40M derived: sum of 2 quarters · filed 2026-02-19 | $39.50M derived: sum of 3 quarters · filed 2026-02-19 | $139.10M 10-K · filed 2026-02-19 |
| 2023-10-01 | $26.30M 10-Q · filed 2024-11-08 | -$600.00K derived: sum of 2 quarters · filed 2024-11-08 | $99.00M 10-Q · filed 2024-11-08 | $185.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | -$26.90M 10-Q · filed 2024-08-01 | $72.70M 10-Q · filed 2024-08-01 | $159.20M derived: sum of 3 quarters · filed 2025-02-27 | $216.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $99.60M 10-Q · filed 2024-05-09 | $186.10M derived: sum of 2 quarters · filed 2025-02-27 | $242.90M derived: sum of 3 quarters · filed 2025-02-27 | $322.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $86.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $143.30M derived: sum of 2 quarters · filed 2025-02-27 | $223.00M derived: sum of 3 quarters · filed 2025-02-27 | $843.70M 10-K · filed 2025-02-27 |
| 2022-10-02 | $56.80M 10-Q · filed 2023-11-02 | $136.50M derived: sum of 2 quarters · filed 2023-11-02 | $757.20M 10-Q · filed 2023-11-02 | $1.13B derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-07-03 | $79.70M 10-Q · filed 2023-08-09 | $700.40M 10-Q · filed 2023-08-09 | $1.08B derived: sum of 3 quarters · filed 2024-08-01 | $1.36B derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-04-03 | $620.70M 10-Q · filed 2023-05-04 | $997.40M derived: sum of 2 quarters · filed 2024-08-01 | $1.28B derived: sum of 3 quarters · filed 2024-08-01 | $1.30B derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-01-02 | $376.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $658.50M derived: sum of 2 quarters · filed 2024-08-01 | $681.80M derived: sum of 3 quarters · filed 2024-08-01 | $906.00M 10-K/A · filed 2024-08-01 |
| 2021-10-03 | $281.80M 10-Q · filed 2022-11-04 | $305.10M derived: sum of 2 quarters · filed 2022-11-04 | $529.30M 10-Q · filed 2022-11-04 | |
| 2021-07-04 | $23.30M 10-Q · filed 2022-08-05 | $247.50M 10-Q · filed 2022-08-05 | ||
| 2021-01-03 | $1.06B 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |